文献速递青光眼白内障与屈光手术

HORIZON随机试验长期结果:Schlemm管微支架联合白内障与青光眼手术的五年疗效

Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery.
PubMed 文献 · Ophthalmology · 2022-02-23

HORIZON前瞻性多中心随机对照试验纳入白内障合并原发性开角型青光眼患者,随机2:1接受白内障手术联合Hydrus微支架或单纯白内障手术。5年随访显示,联合组在无药物眼压≤18 mmHg比例、无药物眼压降幅≥20%比例、用药数量及无药比例方面均优于单纯手术组,联合组需行切口性青光眼手术的累积风险更低,两组角膜内皮细胞丢失率无显著差异。

要点

  • 白内障手术联合Schlemm管微支架5年时无药物眼压≤18 mmHg比例49.5% vs 单纯手术33.8%(P=0.003)。
  • 联合组无药物眼压降幅≥20%比例54.2% vs 单纯手术32.8%(P<0.001)。
  • 联合组需切口性青光眼手术累积风险2.4% vs 单纯手术6.2%(P=0.027)。

核心结论

  • 白内障手术联合Schlemm管微支架安全,5年时较单纯白内障手术降低眼压和用药、减少术后切口性青光眼滤过手术需求。
  • 长期植入物存在未对角膜内皮造成不良影响。

研究设计与样本

  • 前瞻性、多中心、对照随机临床试验。
  • 纳入白内障合并原发性开角型青光眼、使用1种或以上降眼压药物、洗脱后日间眼压22至34 mmHg、无既往切口性青光眼手术的患者。
  • 共369眼随机至Hydrus微支架组,187眼随机至单纯白内障手术组,随机比例2:1。
  • 5年随访完成率80%。

主要发现

  • 5年时无药物眼压≤18 mmHg比例:微支架组49.5% vs 单纯手术组33.8%(P=0.003)。
  • 5年时无药物眼压降幅≥20%比例:微支架组54.2% vs 单纯手术组32.8%(P<0.001)。
  • 降眼压药物数量:微支架组0.5±0.9 vs 单纯手术组0.9±0.9(P<0.001)。
  • 无药比例:微支架组66% vs 单纯手术组46%(P<0.001)。
  • 切口性青光眼手术累积风险:微支架组2.4% vs 单纯手术组6.2%(P=0.027,log-rank检验)。

关键数值与推荐

  • 微支架组与单纯手术组3至60个月角膜内皮细胞丢失率无临床或统计学显著差异(P=0.261)。
  • 两组术前眼压、用药、洗脱后日间眼压及青光眼严重程度匹配良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To present the 5-year results of the HORIZON trial comparing cataract surgery (CS) combined with an intracanalicular microstent with CS alone. DESIGN: Prospective, multicenter, controlled randomized clinical trial. PARTICIPANTS: Patients with cataract and primary open-angle glaucoma treated with 1 or more glaucoma medications, washed-out diurnal intraocular pressure (DIOP) of 22 to 34 mmHg, and no prior incisional glaucoma surgery. METHODS: Eyes were randomized 2:1 to receive a Hydrus Microstent (HMS; Ivantis, Inc) or no stent after successful CS. MAIN OUTCOME MEASURES: Intraocular pressure (IOP), glaucoma medication use, repeat glaucoma surgery, visual acuity, visual field, procedure-related adverse events, and corneal endothelial cell counts. RESULTS: Three hundred sixty-nine eyes were randomized to HMS treatment, and 187 eyes were randomized to CS only. Study groups were well matched for preoperative IOP, medication use, washed-out DIOP, and glaucoma severity. Five-year follow-up was completed in 80% of patients. At 5 years, the HMS group included a higher proportion of eyes with IOP of 18 mmHg or less without medications than the CS group (49.5% vs. 33.8%; P = 0.003), as well as a greater likelihood of IOP reduction of 20% or more without medications than the CS group (54.2% vs. 32.8%; P < 0.001). The number of glaucoma medications was 0.5 ± 0.9 in the HMS group and 0.9 ± 0.9 in the CS group (P < 0.001), and 66% of eyes in the HMS group were medication free compared with 46% in the CS group (P < 0.001). The cumulative risk of incisional glaucoma surgery was lower in the HMS group (2.4% vs. 6.2%; P = 0.027, log-rank test). No clinical or statistically significant differences were found in the rate of endothelial cell loss from 3 to 60 months between the HMS and CS alone groups (P = 0.261). CONCLUSIONS: The addition of a Schlemm's canal microstent in conjunction with CS was safe, resulted in lowered IOP and medication use, and reduced the need for postoperative incisional glaucoma filtration surgery compared with CS after 5 years. Long-term presence of the implant did not affect the corneal endothelium adversely.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Ahmed IIK, De Francesco T, Rhee D, et al. Long-term Outcomes from the HORIZON Randomized Trial for a Schlemm's Canal Microstent in Combination Cataract and Glaucoma Surgery. Ophthalmology. 2022. PMID: 35218867. doi:10.1016/j.ophtha.2022.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。